You make compelling points about the advantages of a $20-30 million cash deal, particularly in terms of funding essential research and buying time for German GBA funding.
All these initiatives could fundamentally shape OncoSil's future in a positive way.
However, I would argue against giving up U.S. rights in return for immediate cash and royalties.
The U.S. market represents a significant opportunity, especially if FDA approval is secured. It would be a long-term play that could pay off exponentially, far outweighing the short-term gains of a quick cash influx.
Holding onto U.S. rights could prove to be vital for the company's long-term valuation and success.
Pancreatic Cancer in the Media, page-61
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.001(9.09%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $18.92K | 1.705M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 13619110 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 5063491 | 9 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |